Children born with a faulty heart valve often face a series of operations, because artificial and animal-derived valves do not grow with them and wear out. GrOwnValve, a Berlin company founded in 2019 by paediatric cardiologist Boris Schmitt and Jasper Emeis as a spin-off of the German Heart Center and Charité, wants to replace them with a valve made during the procedure from the patient's own tissue, shaped on a 3D-printed mould and implanted through a catheter.
The European Innovation Council granted €2.5 million towards a €3.61 million project, and the award included an equity component. The project took the valve into its first patient in 2025. The first published result, from one adult, is encouraging. It is also a single case, written by authors employed by the company, in a study that will not complete until 2031.
Company file
- Legal entity
- GrOwnValve GmbH, Berlin-Charlottenburg HRB 209838 B
- Founded
- September 2019, Berlin
- Leadership
- Boris Schmitt (CEO), Boris Warnack (CTO)
- Products
- AdultValve and ChildValve, with a bioresorbable anchor, in development
- Clinical study
- GECT-DZHK28, Charité-sponsored, seven adults
- Other public funding
- DZHK, EXIST, federal research ministry, IBB Berlin; €510,874 (2026)
- EIC project
- GrownValve, 1 Apr 2022 to 31 Jul 2025, closed
- EIC funding
- Blended finance (grant and equity)
Where GrOwnValve Stands Today
GrOwnValve is in its first clinical study. According to ClinicalTrials.gov, the feasibility study, sponsored by Charité with GrOwnValve as collaborator, started in December 2023, plans to enrol seven patients at the German Heart Center of the Charité in Berlin, was still recruiting in September 2025, and has an estimated primary completion date of January 2031. The first patient was treated in February 2025, according to the CORDIS report, and the company announced it in June 2025, as reported by Cardiovascular Business.
The German register records €510,874 of further public funding in March 2026 for clinical validation of a valve for children, the market the company was built for. We found no announced private funding round.
The Technology: A Valve Made in the Operating Room
The procedure, as described in the first case report, takes a piece of the patient's pericardium, the sac around the heart, and shapes it into a valve on a patient-specific 3D-printed mould based on a CT scan. The valve is mounted on a stent and implanted into the pulmonary position through a catheter, all in one procedure. Because the tissue is the patient's own, the company hopes it will remodel like living tissue, last longer than animal-derived valves and, in children, grow. The EIC project also worked on a bioresorbable stent and a paediatric delivery system.
"Bridge the gap from the laboratory and preclinical trials to our first patients in the clinic."
GrOwnValve on the purpose of its EIC funding, via NKS EIC AcceleratorWhat the EIC Project Promised, and What CORDIS Shows
The project, planned for 36 months according to the German EIC national contact point, ran from April 2022 to July 2025. The CORDIS report lists ISO 13485 certification of the company's quality system, contracts with a notified body, the application and start of the first clinical study, the first-in-human procedures in February 2025 and preclinical testing of bioresorbable stents. It projects savings of about €16 billion a year for Europe's health systems, a figure without published workings.
- First use in patientsDeliveredFirst patient treated in February 2025.
- Quality system and regulatory pathDeliveredISO 13485 and a notified body contract.
- A valve for childrenIn progressPaediatric stent in preclinical testing; clinical validation funded in 2026.
- A valve that lasts a lifetimeUnprovenSix months of data in one patient.
The First Published Case
In July 2026 European Heart Journal Case Reports published the first case: a 35-year-old with severe narrowing of a previously implanted pulmonary valve. Six months after the procedure, the maximum pressure gradient across the valve had fallen from 103 to 14 mmHg, regurgitation had halved from 20% to 10%, and the enlarged right ventricle had shrunk. The authors conclude that the case "demonstrates the feasibility" of making and implanting the valve in one procedure. Their conflict of interest statement reads: "All authors are (partially) employed by GrOwnValve Ltd."
The Money
GrOwnValve has been financed largely by public money: the EIC grant, German research funding from the DZHK, EXIST and the federal research ministry, the Berlin development bank IBB, EU projects and the 2026 paediatric grant, as listed on its website and in the register. Its EIC award was blended finance; neither the EIC nor the company has published the size or terms of the EIC Fund's investment, and we found no private venture round.
What cannot be checked
How much equity the EIC Fund holds, how much money the company has left, and how many patients have been treated since the first are not public. Its accounts are filed but not freely displayed.
Why Europe Should Care
The NKS profile cites 400,000 children born each year worldwide with congenital heart valve defects. A valve that grows with the child would spare many of them repeat operations, and the technology comes out of a European public university hospital. So far, public money has carried most of its development.
What the project promised
A lifelong replacement heart valve for adults and children, made from the patient's own tissue.
What the record shows
A first patient treated and one six-month result published by company-employed authors; the child valve is still preclinical.
The Verdict
A real first step on a very long road
The EIC project did what it set out to do: it moved GrOwnValve from animal studies into humans. The single published case looks good, but it is one adult at six months, reported by the company's own staff. A lifelong valve that grows with children needs years more evidence, starting with a study that runs to 2031, and the public record does not show how that road will be financed.
GrOwnValve has not been asked for comment for this article. It is based entirely on public records, company statements, clinical registry data and EU project data, linked throughout.
Sources
